ARTICLE | Clinical News
GBC-590: Began Phase II trial
April 17, 2000 7:00 AM UTC
SafeScience Inc. (SAFS), Boston, Mass. Product: GBC-590 Business: Cancer Therapeutic category: Cell proliferation Target: Cell surface lectins Description: Carbohydrate lectin inhibitor Indication: Tr...